Miguel Ángel Saavedra Salinas1, Antonio Barrera Cruz2, Antonio Rafael Cabral Castañeda3, Luis Javier Jara Quezada4, C Alejandro Arce-Salinas5, José Álvarez Nemegyei6, Antonio Fraga Mouret7, Javier Orozco Alcalá8, Mario Salazar Páramo9, Claudia Verónica Cruz Reyes10, Lilia Andrade Ortega11, Olga Lidia Vera Lastra12, Claudia Mendoza Pinto13, Antonio Sánchez González10, Polita Del Rocío Cruz Cruz14, Sara Morales Hernández15, Margarita Portela Hernández16, Mario Pérez Cristóbal16, Gabriela Medina García17, Noé Hernández Romero18, María Del Carmen Velarde Ochoa19, José Eduardo Navarro Zarza20, Verónica Portillo Díaz21, Angélica Vargas Guerrero22, María Victoria Goycochea Robles23, José Luis García Figueroa24, Eduardo Barreira Mercado25, Mary Carmen Amigo Castañeda26. 1. Departamento de Reumatología, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS; UNAM, México, Distrito Federal, México. Electronic address: miansaavsa@gmail.com. 2. División de Excelencia Clínica, Área de Desarrollo de Guías de Práctica Clínica, IMSS, México, Distrito Federal, México. 3. Ciencias Médicas F, Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Distrito Federal, México. 4. Dirección de Educación e Investigación, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, UNAM, México, Distrito Federal, México. 5. División de Medicina Interna, Hospital Central Sur de Pemex, México, Distrito Federal, México. 6. Escuela de Medicina, Universidad Anáhuac-Mayab, Mérida, Yucatán, México. 7. Dirección de Educación e Investigación, Secretaría de Salud del Distrito Federal, UNAM, México, Distrito Federal, México. 8. Clínica de Reumatología, Escuela de Medicina, Universidad de Guadalajara, Guadalajara, Jalisco, México. 9. División de Investigación en Salud, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México. 10. Departamento de Reumatología, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS; UNAM, México, Distrito Federal, México. 11. Departamento de Reumatología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Reumatología, UNAM, México, Distrito Federal, México. 12. Departamento de Medicina Interna, Hospital de Especialidades, CMN La Raza, IMSS, UNAM, México, Distrito Federal, México. 13. Unidad de Investigación Enfermedades Autoinmunes Sistémicas, Hospital General Regional n.(o) 36-CIBIOR, Instituto Mexicano del Seguro Social. Unidad de Posgrado, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, México. 14. División de Atención Ginecobstétrica y Perinatal de la Dirección de Prestaciones Médicas del IMSS, México, Distrito Federal, México. 15. Departamento de Perinatología, Hospital Gineco-Obstetricia n.(o)3 Dr. Víctor Manuel Espinosa de los Reyes Sánchez, UMAE, CMN La Raza, IMSS, México, Distrito Federal, México. 16. Departamento de Reumatología, Hospital de Especialidades, CMN Siglo XXI, IMSS, México, Distrito Federal, México. 17. Hospital de Especialidades, CMN La Raza, IMSS, México, Distrito Federal, México. 18. Unidad de Cuidados Intensivos Neonatales, Hospital Gineco-Obstetricia n.(o) 3 Dr. Víctor Manuel Espinosa de los Reyes Sánchez, UMAE, CMN La Raza, IMSS, México, Distrito Federal, México. 19. Departamento de Reumatología e Inmunología Clínica, Hospital General de Zona No. 46, IMSS, Villahermosa, Tabasco, México. 20. Hospital General de Chilpancingo Dr. Raymundo Abarca Alarcón, Chilpancingo, Guerrero, México. 21. Departamento de Medicina Interna, UMAE HGO 4, IMSS, México, Distrito Federal, México. 22. Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, México, Distrito Federal, México. 23. Unidad de investigación en Epidemiología Clínica, Hospital Regional Dr. Carlos Mcgregor Sánchez Navarro, IMSS, México, Distrito Federal, México. 24. Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, México. 25. Reumatología de la Facultad de Medicina, Universidad Autónoma de Querétaro y Universidad del Del Valle de México, Querétaro, Qro., México. 26. Reumatología, Centro Médico ABC, México, Distrito Federal, México.
Abstract
BACKGROUND: Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and fetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients. OBJECTIVES: To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus (SLE), rheumatoid arthritis (RA) and antiphospholipid antibody syndrome (APS). METHODOLOGY: Nominal panels were formed for consensus, systematic search of information, development of clinical questions, processing and grading of recommendations, internal validation by peers, and external validation of the final document. The quality criteria of the AGREE II instrument were followed. RESULTS: The various panels answered the 37 questions related to maternal and fetal care in SLE, RA, and APS, as well as to the use of antirheumatic drugs during pregnancy and lactation. The recommendations were discussed and integrated into a final manuscript. Finally, the corresponding algorithms were developed. We present the recommendations for pregnant women with SLE in this first part. CONCLUSIONS: We believe that the Mexican clinical practice guidelines for the management of pregnancy in women with SLE integrate the best available evidence for the treatment and follow-up of patients with these conditions.
BACKGROUND: Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and fetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients. OBJECTIVES: To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus (SLE), rheumatoid arthritis (RA) and antiphospholipid antibody syndrome (APS). METHODOLOGY: Nominal panels were formed for consensus, systematic search of information, development of clinical questions, processing and grading of recommendations, internal validation by peers, and external validation of the final document. The quality criteria of the AGREE II instrument were followed. RESULTS: The various panels answered the 37 questions related to maternal and fetal care in SLE, RA, and APS, as well as to the use of antirheumatic drugs during pregnancy and lactation. The recommendations were discussed and integrated into a final manuscript. Finally, the corresponding algorithms were developed. We present the recommendations for pregnant women with SLE in this first part. CONCLUSIONS: We believe that the Mexican clinical practice guidelines for the management of pregnancy in women with SLE integrate the best available evidence for the treatment and follow-up of patients with these conditions.
Authors: Miguel Ángel Saavedra; Dafhne Miranda-Hernández; Antonio Sánchez; Sara Morales; Pilar Cruz-Domínguez; Gabriela Medina; Luis Javier Jara Journal: Rheumatol Int Date: 2016-07-07 Impact factor: 2.631